Global In Vitro Diagnostic Ivd Regulatory Affairs Outsourcing Market
Market Size in USD Thousand
CAGR :
% 
USD
674,277.97 Thousand
USD
1,830,957.45 Thousand
2021
2029
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 674,277.97 Thousand |
 Market Size (Forecast Year) |
USD 1,830,957.45 Thousand |
 CAGR |
% |
| Major Markets Players |
|
Global In Vitro Diagnostic (IVD) Regulatory Affairs Outsourcing Market, By Service (Regulatory Writing and Submissions, Regulatory Registration and Clinical Trial Applications, Regulatory Consulting, Legal Representation, Data Management Services, Chemistry Manufacturing and Controls (CMC) Services, and Others), Indication (Oncology, Neurology, Cardiology, Clinical Chemistry and Immunoassays, Precision Medicine, Infectious Diseases, Diabetes, Genetic Testing, HIV/AIDS, Haematology, Drug Testing/Pharmacogenomics, Blood Transfusion, Point of Care, and Others), Deployment Mode (Cloud and On-Premises), Organization Size (Small and Medium Enterprises (SMES) and Large Enterprises), Stage (Clinical, Preclinical, and PMA (Post-Market Authorization)), Class (Class I, Class II, and Class III), End User (Pharmaceutical Companies, Medical Device Companies, Biotechnology Companies, and Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
The healthcare companies faced challenges in keeping up with regulatory standards especially due to the COVID-19 (coronavirus) pandemic. To avail a quality-driven culture for med-tech companies, consulting firms use quality management system (QMS) software. Companies involved in the in vitro diagnostic (IVD) regulatory affairs outsourcing provides project-based support to healthcare organizations.
The deployment of the outsourcing is resulting in the initiation of long-term outsourcing agreements. Global In Vitro Diagnostic (IVD) Regulatory Affairs Outsourcing Market was valued at USD 1.6 billion in 2021 and is expected to reach USD 3.69 billion by 2029, registering a CAGR of 11% during the forecast period of 2022-2029. Pharmaceutical Companies is expected to witness high growth owing to increase in the number of clinical approvals.
Market Definition
Regulatory affairs play a highly crucial role in the vitro diagnostic device (IVD) industry. These affairs are concerned with the lifecycle of various healthcare products, and offers strategic, tactical, and operational support and direction for manufacturing companies to work within the regulatory framework.
Report Scope and Market Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Service (Regulatory Writing and Submissions, Regulatory Registration and Clinical Trial Applications, Regulatory Consulting, Legal Representation, Data Management Services, Chemistry Manufacturing and Controls (CMC) Services, and Others), Indication (Oncology, Neurology, Cardiology, Clinical Chemistry and Immunoassays, Precision Medicine, Infectious Diseases, Diabetes, Genetic Testing, HIV/AIDS, Haematology, Drug Testing/Pharmacogenomics, Blood Transfusion, Point of Care, and Others), Deployment Mode (Cloud and On-Premises), Organization Size (Small and Medium Enterprises (SMES) and Large Enterprises), Stage (Clinical, Preclinical, and PMA (Post-Market Authorization)), Class (Class I, Class II, and Class III), End User (Pharmaceutical Companies, Medical Device Companies, Biotechnology Companies, and Others) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. |
|
Market Players Covered |
Freyr Solutions (India), PPD Inc. (US), EMERGO (US), ICON (Healthcare), Parexel International Corporation (US), CRITERIUM, INC. (US), Groupe ProductLife S.A. (France), Labcorp Drug Development (US), WuXi AppTec (China), Genpact (US), Medpace (US), Dor Pharmaceutical Services (Israel), Qserve (Netherlands), among others |
|
Market Opportunities |
|
In Vitro Diagnostic (IVD) Regulatory Affairs Outsourcing Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:
- High Use in the Healthcare Industry
The increase in the deployment of the outsourcing services across the healthcare sector acts as one of the major factors driving the growth of in vitro diagnostic (IVD) regulatory affairs outsourcing market. The surge in geographical expansion activities aiming for speedy approvals in local markets further assists in the growth.
- Research and Development
The rise in the research and development activities increasing the volume of clinical trial applications and product registration accelerate the market growth.
- Clinical Approvals
An increase in demand for in vitro diagnostic (IVD) regulatory affairs outsourcing is being witnessed as companies are under constant pressure to procure timely clinical approvals from regulators. The demand for regulatory affairs services is increasing due to such actions.
Opportunities
Furthermore, development of disease-specific biomarkers and tests, and significance of companion diagnostics extend profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, surge in investments will further expand the market.
Restraints/Challenges
On the other hand, changing regulations regarding medical devices and in vitro diagnostic (IVD) regulatory affairs outsourcing are expected to obstruct market growth. Also, lack of infrastructure in healthcare service is projected to challenge the in vitro diagnostic (IVD) regulatory affairs outsourcing market in the forecast period of 2022-2029.
This in vitro diagnostic (IVD) regulatory affairs outsourcing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on in vitro diagnostic (IVD) regulatory affairs outsourcing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Covid-19 Impact on Diagnostic Tests Market
COVID-19 had a negative impact on the healthcare sector. Major Key players adapted innovative strategies to the rapidly changing situation during the outbreak of the COVID-19. Countries took critical healthcare changes until the crisis took a back seat. Healthcare reforms are expected to witness cost containment, increased access and technological progress in the coming years. An increase in demand for in vitro diagnostic (IVD) regulatory affairs outsourcing was witnessed owing to the emphasis on the importance of remote diagnosis, care, and consultation. These services decline the burden on hospitals in the post-pandemic scenario.
Recent Developments
- USA-9 Technology Magazine Listed Freyr in the “10 Best Technology Solution Providers of 2021 in November’2021. USA-9.com is a Technology Magazine that has listed Freyr Solutions, a leading global regulatory solution, and services provider, as the “10 Best Technology Solution Providers of 2021 as Fryer continues to design innovative software solutions and support clients in their respective compliance objectives. This has helped company to increase its popularity.
Global In Vitro Diagnostic (IVD) Regulatory Affairs Outsourcing Market Scope and Market Size
The in vitro diagnostic (IVD) regulatory affairs outsourcing market is segmented on the basis of services, indication, deployment mode, organization size, stage, class and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Services
- Regulatory Writing and Submissions
- Regulatory Registration and Clinical Trial Applications
- Regulatory Consulting
- Legal Representation
- Data Management Services
- Chemistry Manufacturing and Controls (CMC) Services
- Others
On the basis of services, the global in vitro diagnostic (IVD) regulatory affairs outsourcing market is segmented into regulatory writing and submissions, regulatory registration and clinical trial applications, regulatory consulting, legal representation, data management services, chemistry manufacturing and controls (CMC) services, and others.
Indication
- Oncology
- Neurology
- Cardiology
- Clinical Chemistry and Immunoassays
- Precision Medicine
- Infectious Diseases
- Diabetes
- Genetic Testing
- HIV/AIDS
- Haematology
- Drug Testing/Pharmacogenomics
- Blood Transfusion
- Point Of Care
- Others
On the basis of indication, the global in vitro diagnostic (IVD) regulatory affairs outsourcing market is segmented into oncology, neurology, cardiology, clinical chemistry and immunoassays, precision medicine, infectious diseases, diabetes, genetic testing, HIV/AIDS, haematology, drug testing/pharmacogenomics, blood transfusion, point of care, and others.
Deployment Mode
- Cloud
- On-Premises
On the basis of deployment mode, the global in vitro diagnostic (IVD) regulatory affairs outsourcing market is segmented into cloud and on-premises.
Organization Size
- Small and Medium Enterprises (Smes)
- Large Enterprises
On the basis of organization size, the global in vitro diagnostic (IVD) regulatory affairs outsourcing market is segmented into small and medium enterprises (SMES) and large enterprises.
Stage
- Clinical
- Preclinical
- PMA (Post-Market Authorization)
On the basis of stage, the global in vitro diagnostic (IVD) regulatory affairs outsourcing market is segmented into clinical, preclinical, and PMA (post-market authorization).
Class
- Class I
- Class II
- Class III
On the basis of class, the global in vitro diagnostic (IVD) regulatory affairs outsourcing market is segmented into class I, class II, and class III.
End User
- Pharmaceutical Companies
- Medical Device Companies
- Biotechnology Companies
- Others
On the basis of end user, the global in vitro diagnostic (IVD) regulatory affairs outsourcing market is segmented into pharmaceutical companies, medical device companies, biotechnology companies, and others.
In Vitro Diagnostic (IVD) Regulatory Affairs Outsourcing Market Regional Analysis/Insights
The in vitro diagnostic (IVD) regulatory affairs outsourcing market is analysed and market size insights and trends are provided by country, services, indication, deployment mode, organization size, stage, class and end user as referenced above.
The countries covered in the in vitro diagnostic (IVD) regulatory affairs outsourcing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific (APAC) dominates the in vitro diagnostic (IVD) regulatory affairs outsourcing market because of the rise in number of clinical trials and the rising number of companies within the region.
North America is expected to witness significant growth during the forecast period of 2022 to 2029 due to the presence of key pharmaceutical and medical devices companies and the rise in the research and development spending in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The in vitro diagnostic (IVD) regulatory affairs outsourcing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for in vitro diagnostic (IVD) regulatory affairs outsourcing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the in vitro diagnostic (IVD) regulatory affairs outsourcing market. The data is available for historic period 2010-2020.
Competitive Landscape and In Vitro Diagnostic (IVD) Regulatory Affairs Outsourcing Market Share Analysis
The in vitro diagnostic (IVD) regulatory affairs outsourcing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to in vitro diagnostic (IVD) regulatory affairs outsourcing market.
Some of the major players operating in the in vitro diagnostic (IVD) regulatory affairs outsourcing market are:
- Freyr Solutions (India)
- PPD Inc. (US)
- EMERGO (US)
- ICON (Healthcare)
- Parexel International Corporation (US)
- CRITERIUM, INC. (US)
- Groupe ProductLife S.A. (France)
- Labcorp Drug Development (US)
- WuXi AppTec (China)
- Genpact (US)
- Medpace (US)
- Dor Pharmaceutical Services (Israel)
- Qserve (Netherlands)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MULTIVARIATE MODELLING
2.2.4 TOP TO BOTTOM ANALYSIS
2.2.5 STANDARDS OF MEASUREMENT
2.2.6 VENDOR SHARE ANALYSIS
2.2.7 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.8 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3. MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4. PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5. INDUSTRY INSIGHTS
5.1 MICRO AND MACRO ECONOMIC FACTORS
5.2 PENETRATION AND GROWTH PROSPECT MAPPING
5.3 KEY PRICING STRATEGIES
5.4 INTERVIEWS WITH SPECIALIST
5.5 ANALYIS AND RECOMMENDATION
6. INTELLECTUAL PROPERTY (IP) PORTFOLIO
6.1 PATENT QUALITY AND STRENGTH
6.2 PATENT FAMILIES
6.3 LICENSING AND COLLABORATIONS
6.4 COMPETITIVE LANDSCAPE
6.5 IP STRATEGY AND MANAGEMENT
6.6 OTHER
7. COST ANALYSIS BREAKDOWN
8. TECHNONLOGY ROADMAP
9. INNOVATION TRACKER AND STRATEGIC ANALYSIS
9.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
9.1.1 JOINT VENTURES
9.1.2 MERGERS AND ACQUISITIONS
9.1.3 LICENSING AND PARTNERSHIP
9.1.4 TECHNOLOGY COLLABORATIONS
9.1.5 STRATEGIC DIVESTMENTS
9.2 NUMBER OF PRODUCTS IN DEVELOPMENT
9.3 STAGE OF DEVELOPMENT
9.4 TIMELINES AND MILESTONES
9.5 INNOVATION STRATEGIES AND METHODOLOGIES
9.6 RISK ASSESSMENT AND MITIGATION
9.7 FUTURE OUTLOOK
10. REGULATORY COMPLIANCE
10.1 REGULATORY AUTHORITIES
10.2 REGULATORY CLASSIFICATIONS
10.2.1 CLASS I
10.2.2 CLASS II
10.2.3 CLASS III
10.3 REGULATORY SUBMISSIONS
10.4 INTERNATIONAL HARMONIZATION
10.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
10.6 REGULATORY CHALLENGES AND STRATEGIES
11. REIMBURSEMENT FRAMEWORK
12. OPPUTUNITY MAP ANALYSIS
13. INSTALLED BASE DATA
14. VALUE CHAIN ANALYSIS
15. HEALTHCARE ECONOMY
15.1 HEALTHCARE EXPENDITURE
15.2 CAPITAL EXPENDITURE
15.3 CAPEX TRENDS
15.4 CAPEX ALLOCATION
15.5 FUNDING SOURCES
15.6 INDUSTRY BENCHMARKS
15.7 GDP RATION IN OVERALL GDP
15.8 HEALTHCARE SYSTEM STRUCTURE
15.9 GOVERNMENT POLICIES
15.10 ECONOMIC DEVELOPMENT
16. GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE
16.1 OVERVIEW
16.2 REGULATORY WRITING & SUBMISSIONS
16.3 REGULATORY REGISTRATION & CLINICAL TRIAL APPLICATIONS
16.4 REGULATORY CONSULTING
16.5 LEGAL REPRESENTATION
16.6 DATA MANAGEMENT SERVICES
16.7 CHEMISTRY MANUFACTURING AND CONTROLS (CMC) SERVICES
16.8 OTHERS
17. GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION
17.1 OVERVIEW
17.2 ONCOLOGY
17.3 NEUROLOGY
17.4 CARDIOLOGY
17.5 CLINICAL CHEMISTRY AND IMMUNOASSAYS
17.6 PRECISION MEDICINE
17.7 INFECTIOUS DISEASES
17.7.1 SEPSIS
17.7.2 VIROLOGY
17.7.3 BACTERIOLOGY
17.7.4 MICROBIOLOGY AND MYCOLOGY
17.7.5 HEPATITIS B
17.7.6 HEPATITIS C
17.7.7 SYPHILIS
17.7.8 TUBERCULOSIS
17.7.9 MALARIA
17.7.10 HUMAN PAPILLOMAVIRUS (HPV) INFECTION
17.7.11 OTHERS
17.8 DIABETES
17.9 GENETIC TESTING
17.10 HIV/AIDS
17.11 HAEMATOLOGY
17.12 DRUG TESTING/PHARMACOGENOMICS
17.13 BLOOD TRANSFUSION
17.14 OTHERS
18. GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE
18.1 OVERVIEW
18.2 PRECLINICAL
18.3 CLINICAL
18.4 PMA (POST MARKET AUTHORIZATION)
19. GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS
19.1 OVERVIEW
19.2 CLASS I
19.3 CLASS II
19.4 CLASS III
20. GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE
20.1 OVERVIEW
20.2 POINT-OF-CARE (POC) IVD PRODUCT
20.3 LABORATORY-DEVELOPED TESTS (LDTS) IVD PRODUCT
20.4 COMPANION DIAGNOSTICS IVD PRODUCT
20.5 DIRECT-TO-CONSUMER (DTC) TESTING IVD PRODUCT
20.6 OTHERS IVD PRODUCT
21. GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE
21.1 OVERVIEW
21.2 CLOUD
21.3 ON-PREMISES
22. GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZARION SIZE
22.1 OVERVIEW
22.2 SMALL & MEDIUM ENTERPRISES (SMES)
22.3 LARGE ENTERPRISES
23. GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER
23.1 OVERVIEW
23.2 PHARMACEUTICAL COMPANIES
23.2.1 BY ORGANIZATION SIZE
23.2.1.1. SMALL & MEDIUM ENTERPRISES (SMES)
23.2.1.2. LARGE ENTERPRISES
23.2.2 BY SERVICE
23.2.2.1. REGULATORY WRITING & SUBMISSIONS
23.2.2.2. REGULATORY REGISTRATION & CLINICAL TRIAL APPLICATIONS
23.2.2.3. REGULATORY CONSULTING
23.2.2.4. LEGAL REPRESENTATION
23.2.2.5. DATA MANAGEMENT SERVICES
23.2.2.6. CHEMISTRY MANUFACTURING AND CONTROLS (CMC) SERVICES
23.2.2.7. OTHERS
23.3 MEDICAL DEVICE COMPANIES
23.3.1 BY ORGANIZATION SIZE
23.3.1.1. SMALL & MEDIUM ENTERPRISES (SMES)
23.3.1.2. LARGE ENTERPRISES
23.3.2 BY SERVICE
23.3.2.1. REGULATORY WRITING & SUBMISSIONS
23.3.2.2. REGULATORY REGISTRATION & CLINICAL TRIAL APPLICATIONS
23.3.2.3. REGULATORY CONSULTING
23.3.2.4. LEGAL REPRESENTATION
23.3.2.5. DATA MANAGEMENT SERVICES
23.3.2.6. CHEMISTRY MANUFACTURING AND CONTROLS (CMC) SERVICES
23.3.2.7. OTHERS
23.4 BIOTECHNOLOGY COMPANIES
23.4.1 BY ORGANIZATION SIZE
23.4.1.1. SMALL & MEDIUM ENTERPRISES (SMES)
23.4.1.2. LARGE ENTERPRISES
23.4.2 BY SERVICE
23.4.2.1. REGULATORY WRITING & SUBMISSIONS
23.4.2.2. REGULATORY REGISTRATION & CLINICAL TRIAL APPLICATIONS
23.4.2.3. REGULATORY CONSULTING
23.4.2.4. LEGAL REPRESENTATION
23.4.2.5. DATA MANAGEMENT SERVICES
23.4.2.6. CHEMISTRY MANUFACTURING AND CONTROLS (CMC) SERVICES
23.4.2.7. OTHERS
23.5 OTHERS
24. GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION
24.1 GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
24.1.1 NORTH AMERICA
24.1.1.1. U.S.
24.1.1.2. CANADA
24.1.1.3. MEXICO
24.1.2 EUROPE
24.1.2.1. GERMANY
24.1.2.2. FRANCE
24.1.2.3. U.K.
24.1.2.4. ITALY
24.1.2.5. SPAIN
24.1.2.6. RUSSIA
24.1.2.7. TURKEY
24.1.2.8. BELGIUM
24.1.2.9. NETHERLANDS
24.1.2.10. SWITZERLAND
24.1.2.11. REST OF EUROPE
24.1.3 ASIA-PACIFIC
24.1.3.1. JAPAN
24.1.3.2. CHINA
24.1.3.3. SOUTH KOREA
24.1.3.4. INDIA
24.1.3.5. AUSTRALIA
24.1.3.6. SINGAPORE
24.1.3.7. THAILAND
24.1.3.8. MALAYSIA
24.1.3.9. INDONESIA
24.1.3.10. PHILIPPINES
24.1.3.11. REST OF ASIA-PACIFIC
24.1.4 SOUTH AMERICA
24.1.4.1. BRAZIL
24.1.4.2. ARGENTINA
24.1.4.3. REST OF SOUTH AMERICA
24.1.5 MIDDLE EAST AND AFRICA
24.1.5.1. SOUTH AFRICA
24.1.5.2. EGYPT
24.1.5.3. ISRAEL
24.1.5.4. UAE
24.1.5.5. SAUDI ARABIA
24.1.5.6. REST OF MIDDLE EAST AND AFRICA
24.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
25. GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET, COMPANY LANDSCAPE
25.1 COMPANY SHARE ANALYSIS: GLOBAL
25.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
25.3 COMPANY SHARE ANALYSIS: EUROPE
25.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
25.5 MERGERS & ACQUISITIONS
25.6 NEW PRODUCT DEVELOPMENT & APPROVALS
25.7 EXPANSIONS
25.8 REGULATORY CHANGES
25.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
26. GLOBAL IN VITRO DIAGNOSTIC (IVD) REGULATORY AFFAIRS OUTSOURCING MARKET, COMPANY PROFILE
26.1 FREYR SOLUTIONS
26.1.1 COMPANY OVERVIEW
26.1.2 COMPANY SNAPSHOT
26.1.3 REVENUE ANALYSIS
26.1.4 PRODUCT PORTFOLIO
26.1.5 RECENT DEVELOPMENTS
26.2 AXSOURCE CONSULTING INC.
26.2.1 COMPANY OVERVIEW
26.2.2 COMPANY SNAPSHOT
26.2.3 REVENUE ANALYSIS
26.2.4 PRODUCT PORTFOLIO
26.2.5 RECENT DEVELOPMENTS
26.3 LORENZ LIFE SCIENCES GROUP
26.3.1 COMPANY OVERVIEW
26.3.2 COMPANY SNAPSHOT
26.3.3 REVENUE ANALYSIS
26.3.4 PRODUCT PORTFOLIO
26.3.5 RECENT DEVELOPMENTS
26.4 LABORATORY CORPORATION OF AMERICA HOLDINGS
26.4.1 COMPANY OVERVIEW
26.4.2 COMPANY SNAPSHOT
26.4.3 REVENUE ANALYSIS
26.4.4 PRODUCT PORTFOLIO
26.4.5 RECENT DEVELOPMENTS
26.5 REG IQ PTY LTD.
26.5.1 COMPANY OVERVIEW
26.5.2 COMPANY SNAPSHOT
26.5.3 REVENUE ANALYSIS
26.5.4 PRODUCT PORTFOLIO
26.5.5 RECENT DEVELOPMENTS
26.6 PROMEDICA INTERNATIONAL, A CALIFORNIA CORPORATION (IUVO BIOSCIENCES)
26.6.1 COMPANY OVERVIEW
26.6.2 COMPANY SNAPSHOT
26.6.3 REVENUE ANALYSIS
26.6.4 PRODUCT PORTFOLIO
26.6.5 RECENT DEVELOPMENTS
26.7 MAKROCARE
26.7.1 COMPANY OVERVIEW
26.7.2 COMPANY SNAPSHOT
26.7.3 REVENUE ANALYSIS
26.7.4 PRODUCT PORTFOLIO
26.7.5 RECENT DEVELOPMENTS
26.8 EMERGO BY UL
26.8.1 COMPANY OVERVIEW
26.8.2 COMPANY SNAPSHOT
26.8.3 REVENUE ANALYSIS
26.8.4 PRODUCT PORTFOLIO
26.8.5 RECENT DEVELOPMENTS
26.9 ICON PLC
26.9.1 COMPANY OVERVIEW
26.9.2 COMPANY SNAPSHOT
26.9.3 REVENUE ANALYSIS
26.9.4 PRODUCT PORTFOLIO
26.9.5 RECENT DEVELOPMENTS
26.10 WUXI APPTEC
26.10.1 COMPANY OVERVIEW
26.10.2 COMPANY SNAPSHOT
26.10.3 REVENUE ANALYSIS
26.10.4 PRODUCT PORTFOLIO
26.10.5 RECENT DEVELOPMENTS
26.11 THERMO FISHER SCIENTIFIC INC.
26.11.1 COMPANY OVERVIEW
26.11.2 COMPANY SNAPSHOT
26.11.3 REVENUE ANALYSIS
26.11.4 PRODUCT PORTFOLIO
26.11.5 RECENT DEVELOPMENTS
26.12 CHARLES RIVER LABORATORIES.
26.12.1 COMPANY OVERVIEW
26.12.2 COMPANY SNAPSHOT
26.12.3 REVENUE ANALYSIS
26.12.4 PRODUCT PORTFOLIO
26.12.5 RECENT DEVELOPMENTS
26.13 ACCELL CLINICAL RESEARCH, LLC
26.13.1 COMPANY OVERVIEW
26.13.2 COMPANY SNAPSHOT
26.13.3 REVENUE ANALYSIS
26.13.4 PRODUCT PORTFOLIO
26.13.5 RECENT DEVELOPMENTS
26.14 PAREXEL INTERNATIONAL (MA) CORPORATION
26.14.1 COMPANY OVERVIEW
26.14.2 COMPANY SNAPSHOT
26.14.3 REVENUE ANALYSIS
26.14.4 PRODUCT PORTFOLIO
26.14.5 RECENT DEVELOPMENTS
26.15 METECON GMBH
26.15.1 COMPANY OVERVIEW
26.15.2 COMPANY SNAPSHOT
26.15.3 REVENUE ANALYSIS
26.15.4 PRODUCT PORTFOLIO
26.15.5 RECENT DEVELOPMENTS
26.16 GENPACT
26.16.1 COMPANY OVERVIEW
26.16.2 COMPANY SNAPSHOT
26.16.3 REVENUE ANALYSIS
26.16.4 PRODUCT PORTFOLIO
26.16.5 RECENT DEVELOPMENTS
26.17 CRITERIUM, INC
26.17.1 COMPANY OVERVIEW
26.17.2 COMPANY SNAPSHOT
26.17.3 REVENUE ANALYSIS
26.17.4 PRODUCT PORTFOLIO
26.17.5 RECENT DEVELOPMENTS
26.18 MEDPACE
26.18.1 COMPANY OVERVIEW
26.18.2 COMPANY SNAPSHOT
26.18.3 REVENUE ANALYSIS
26.18.4 PRODUCT PORTFOLIO
26.18.5 RECENT DEVELOPMENTS
26.19 GROUPE PRODUCTLIFE S.A.
26.19.1 COMPANY OVERVIEW
26.19.2 COMPANY SNAPSHOT
26.19.3 REVENUE ANALYSIS
26.19.4 PRODUCT PORTFOLIO
26.19.5 RECENT DEVELOPMENTS
26.20 DOR PHARMACEUTICAL SERVICES
26.20.1 COMPANY OVERVIEW
26.20.2 COMPANY SNAPSHOT
26.20.3 REVENUE ANALYSIS
26.20.4 PRODUCT PORTFOLIO
26.20.5 RECENT DEVELOPMENTS
26.21 QSERVE
26.21.1 COMPANY OVERVIEW
26.21.2 COMPANY SNAPSHOT
26.21.3 REVENUE ANALYSIS
26.21.4 PRODUCT PORTFOLIO
26.21.5 RECENT DEVELOPMENTS
26.22 ORTHO CLINICAL DIAGNOSTICS.
26.22.1 COMPANY OVERVIEW
26.22.2 COMPANY SNAPSHOT
26.22.3 REVENUE ANALYSIS
26.22.4 PRODUCT PORTFOLIO
26.22.5 RECENT DEVELOPMENTS
26.23 ANGSTROM BIOTECH PVT. LTD.
26.23.1 COMPANY OVERVIEW
26.23.2 COMPANY SNAPSHOT
26.23.3 REVENUE ANALYSIS
26.23.4 PRODUCT PORTFOLIO
26.23.5 RECENT DEVELOPMENTS
26.24 RQM+
26.24.1 COMPANY OVERVIEW
26.24.2 COMPANY SNAPSHOT
26.24.3 REVENUE ANALYSIS
26.24.4 PRODUCT PORTFOLIO
26.24.5 RECENT DEVELOPMENTS
26.25 REGULATORY COMPLIANCES ASSOCIATES (SOTERA HEALTH)
26.25.1 COMPANY OVERVIEW
26.25.2 COMPANY SNAPSHOT
26.25.3 REVENUE ANALYSIS
26.25.4 PRODUCT PORTFOLIO
26.25.5 RECENT DEVELOPMENTS
26.26 RESEARCHDX
26.26.1 COMPANY OVERVIEW
26.26.2 COMPANY SNAPSHOT
26.26.3 REVENUE ANALYSIS
26.26.4 PRODUCT PORTFOLIO
26.26.5 RECENT DEVELOPMENTS
26.27 CMIC HOLDINGS CO., LTD.
26.27.1 COMPANY OVERVIEW
26.27.2 COMPANY SNAPSHOT
26.27.3 REVENUE ANALYSIS
26.27.4 PRODUCT PORTFOLIO
26.27.5 RECENT DEVELOPMENTS
26.28 NORTH AMERICAN SCIENCE ASSOCIATES, LLC
26.28.1 COMPANY OVERVIEW
26.28.2 COMPANY SNAPSHOT
26.28.3 REVENUE ANALYSIS
26.28.4 PRODUCT PORTFOLIO
26.28.5 RECENT DEVELOPMENTS
26.29 QARAD BV
26.29.1 COMPANY OVERVIEW
26.29.2 COMPANY SNAPSHOT
26.29.3 REVENUE ANALYSIS
26.29.4 PRODUCT PORTFOLIO
26.29.5 RECENT DEVELOPMENTS
26.30 TRANSCRIP
26.30.1 COMPANY OVERVIEW
26.30.2 COMPANY SNAPSHOT
26.30.3 REVENUE ANALYSIS
26.30.4 PRODUCT PORTFOLIO
26.30.5 RECENT DEVELOPMENTS
26.31 CLIN-R+
26.31.1 COMPANY OVERVIEW
26.31.2 COMPANY SNAPSHOT
26.31.3 REVENUE ANALYSIS
26.31.4 PRODUCT PORTFOLIO
26.31.5 RECENT DEVELOPMENTS
26.32 VCLS
26.32.1 COMPANY OVERVIEW
26.32.2 COMPANY SNAPSHOT
26.32.3 REVENUE ANALYSIS
26.32.4 PRODUCT PORTFOLIO
26.32.5 RECENT DEVELOPMENTS
26.33 PROPHARMA GROUP
26.33.1 COMPANY OVERVIEW
26.33.2 COMPANY SNAPSHOT
26.33.3 REVENUE ANALYSIS
26.33.4 PRODUCT PORTFOLIO
26.33.5 RECENT DEVELOPMENTS
26.34 ARRIELLO IRELAND LIMITED
26.34.1 COMPANY OVERVIEW
26.34.2 COMPANY SNAPSHOT
26.34.3 REVENUE ANALYSIS
26.34.4 PRODUCT PORTFOLIO
26.34.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
27. RELATED REPORTS
28. QUESTIONNAIRE
29. ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
